The semaglutide sequence: how the dose ladder works and why it matters

Why the trial data shaped a gradual ramp, not an immediate full dose

The STEP 1 trial, published in the New England Journal of Medicine, enrolled adults with obesity over 68 weeks and demonstrated an average body-weight reduction of around 15% at the 2.4 mg maintenance dose. Crucially, the protocol did not ask participants to start at 2.4 mg. It started them at 0.25 mg, a dose chosen not because it produces meaningful weight loss, but because it lets the gut adapt to the medicine. Gastric emptying slows, appetite signals shift, and the body's response to GIP and GLP-1 receptor activation takes time to settle. Jumping straight to a higher dose would expose patients to nausea and vomiting before those adaptations occur.

The regulatory authorities took that evidence seriously. The approved sequence in the UK reflects the trial protocol directly: a deliberate climb rather than an immediate therapeutic hit. Prescribers can slow the sequence down if a patient is struggling at a particular step. Accelerating it is not recommended.

For the newer 7.2 mg pathway, the starting point is still 0.25 mg. The top dose is simply higher, and the titration continues beyond 2.4 mg for patients who tolerate the climb and need further effect.

The injection sequence, step by step, what each phase is actually doing

The Wegovy injection sequence runs: 0.25 mg (weeks 1–4), 0.5 mg (weeks 5–8), 1.0 mg (weeks 9–12), 1.7 mg (weeks 13–16), then 2.4 mg from week 17 onward as the maintenance dose. Each four-week period serves a purpose. The earliest steps are tolerability phases, the body is adjusting. Meaningful appetite suppression tends to build through the middle steps. By maintenance, most patients have found their rhythm: reduced hunger, slower gastric emptying, better satiety from smaller meals.

You can read more about how semaglutide works as a medicine on the semaglutide overview page, including a closer look at the semaglutide peptide sequence that gives the molecule its distinctive action. The practical question patients often raise is what happens if a dose is delayed, whether a weekly injection falls on a bank holiday or the delivery lands late before a trip. That is always a question for your prescriber or the Patient Information Leaflet, not something to resolve by guessing. If you want to understand how injection frequency interacts with the sequence, that page covers the weekly timing rules in detail.

Storage across the sequence stays consistent: refrigerate between 2–8°C; the exact window for room-temperature use is stated in the SmPC rather than here, because it matters to get that detail right.

The oral tablet sequence: a different ladder with different rules

The Wegovy tablet (approved by the MHRA on 11 June 2026 as the first oral GLP-1 medicine licensed in the UK for weight management) follows a separate escalation entirely. The steps are 1.5 mg, then 4 mg, then 9 mg, reaching the 25 mg maintenance dose, with a minimum of one month at each level. Those strengths are specific to the weight-management tablet; they are not the same as the diabetes tablet Rybelsus, which uses 3 mg, 7 mg and 14 mg steps. Mixing up the two products is a meaningful clinical risk.

The tablet's timing rule is strict in a way the injection is not: take it first thing in the morning on an empty stomach, with a small amount of plain water (up to around 120 ml), then wait at least 30 minutes before any food, other drinks, or oral medicines. The before-the-kettle-goes-on habit is genuinely useful here, the tablet needs to absorb before anything else enters the stomach. No refrigeration is required, which many patients find convenient for travel. The Wegovy treatment page covers both the injection and tablet formats if you want a side-by-side picture.

Phase 3 trial data (OASIS 4, 64 weeks) showed an average weight reduction of around 13.6% compared to around 2.4% on placebo; among participants who stayed fully adherent, that figure rose to approximately 16.6%. The sequence mattered there too: dose escalation was tied to tolerability, and gastrointestinal effects were most common early in the ramp.

What a prescriber considers before moving you along the sequence

Eligibility for semaglutide under the licensed criteria covers adults with a BMI of 30 or above, or 27 to 29.9 with at least one weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol or obstructive sleep apnoea. A lower BMI threshold applies for some ethnic backgrounds under UK guidance. Meeting those numbers is the starting point; a prescriber also looks at current medications, medical history, and how well the previous dose was tolerated before moving a patient to the next step.

At nume, a GPhC-registered Independent Prescriber personally reviews every consultation and every repeat order. No algorithm decides whether the sequence moves forward. That review happens the same day for orders placed before 12pm, Monday to Friday, worth bearing in mind if payday falls on a Friday and you want treatment in hand for the following week. For questions about what the sequence costs in a private setting, the Wegovy pricing page sets out the context honestly. If you have questions about side effects that sometimes appear earlier in the sequence, our FAQs are a useful starting point, and the contact page connects you directly with the team.

The MHRA's Yellow Card scheme lets patients report any suspected side effects directly, a useful reminder that clinical oversight does not end once a prescription is issued. If you think the semaglutide sequence might be right for you, the sensible next step is a clinical conversation rather than a guess about which dose to start on, and if you are curious about the structural detail behind the medicine, our page on the semaglutide amino acid sequence explains how that chemistry underpins its effects. Check your eligibility with our prescribers and get a same-day clinical review.